Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

HUBER+SUHNER nominated by largest automotive supplier as development and production partner for radar antennas
HUBER+SUHNER nominated by largest automotive supplier as development and production partner for radar antennas
HUBER+SUHNER nominated by largest automotive supplier as development and production partner for radar antennas
Combination of Komax and Schleuniger completed
Combination of Komax and Schleuniger completed
Combination of Komax and Schleuniger completed
Metall Zug AG: Closing of the combination between Schleuniger and Komax has been completed
Metall Zug AG: Closing of the combination between Schleuniger and Komax has been completed
Metall Zug AG: Closing of the combination between Schleuniger and Komax has been completed
GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody: https://mms.businesswire.com/media/20210924005283/en/519367/5/GeNeuro_-_logo.jpg
GeNeuro : Two Studies on ALS Published in Annals of Neurology Demonstrate the Neurotoxic Role of Human Endogenous Retrovirus Envelope Protein (HERV-K/HML-2 ENV) and the Rationale for Targeted Therapy With Specific Antibody


GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic

Private Equity Holding AG: Cancellation of Registered Shares
Private Equity Holding AG: Cancellation of Registered Shares
Private Equity Holding AG: Cancellation of Registered Shares
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
DGAP-News: BB BIOTECH AG: Moderna was just the beginning
Partners Group reports strong H1 management fee growth driven by robust client demand; lower performance fees in line with guidance
Partners Group reports strong H1 management fee growth driven by robust client demand; lower performance fees in line with guidance
Partners Group reports strong H1 management fee growth driven by robust client demand; lower performance fees in line with guidance
TX Group with stable revenue (organically 12% above previous year) - high paper price, investments and depreciation and amortisation affect earnings
TX Group with stable revenue (organically 12% above previous year) - high paper price, investments and depreciation and amortisation affect earnings
TX Group with stable revenue (organically 12% above previous year) - high paper price, investments and depreciation and amortisation affect earnings
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Kinarus Therapeutics initiates KIN001 Phase II KINFAST clinical trial in COVID-19 outpatients
Markus Heusser proposed for election as Chairman of the Board of Directors and successor to Urs Kaufmann
Markus Heusser proposed for election as Chairman of the Board of Directors and successor to Urs Kaufmann
Markus Heusser proposed for election as Chairman of the Board of Directors and successor to Urs Kaufmann
Edisun Power Europe AG: Record profit with positive outlook
Edisun Power Europe AG: Record profit with positive outlook
Edisun Power Europe AG: Record profit with positive outlook
SFS exceeds its growth targets in the first half of 2022
SFS exceeds its growth targets in the first half of 2022
SFS exceeds its growth targets in the first half of 2022
Zug Estates achieves increase in net profit thanks to successes in both operating segments
Zug Estates achieves increase in net profit thanks to successes in both operating segments
Zug Estates achieves increase in net profit thanks to successes in both operating segments
HIAG achieves record results in the first half of business year 2022
HIAG achieves record results in the first half of business year 2022
HIAG achieves record results in the first half of business year 2022
Change in shareholding of significant shareholders at Burkhalter Holding Ltd
Change in shareholding of significant shareholders at Burkhalter Holding Ltd
Change in shareholding of significant shareholders at Burkhalter Holding Ltd
Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs
Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs
Edison Investment Research Limited: Kinarus Therapeutics (KNRS): Initiation - A unique combination targeting unmet needs
Evolva with record half-yearly sales and new mid-term plan
Evolva with record half-yearly sales and new mid-term plan
Evolva with record half-yearly sales and new mid-term plan
Baloise achieves solid financial results for the first half of 2022 as it enters a new strategic phase
Baloise achieves solid financial results for the first half of 2022 as it enters a new strategic phase
Baloise achieves solid financial results for the first half of 2022 as it enters a new strategic phase
Swiss Prime Site: profit up by over 6%
Swiss Prime Site: profit up by over 6%
Swiss Prime Site: profit up by over 6%
ALSO offers holistic concept for marketing the Gaming Place
ALSO offers holistic concept for marketing the Gaming Place
ALSO offers holistic concept for marketing the Gaming Place
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Relief Therapeutics files registration statement on form F-1 with the U.S. Securities and Exchange Commission
Swiss Life successfully places a Senior Bond totalling EUR 700 million
Swiss Life successfully places a Senior Bond totalling EUR 700 million
Swiss Life successfully places a Senior Bond totalling EUR 700 million
Arbonia with a challenging first half-year of 2022
Arbonia with a challenging first half-year of 2022
Arbonia with a challenging first half-year of 2022
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Sonova to enable fully immersive conversations in virtually any situation with new Lumity platform
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones